Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Heron Therapeutics ( (HRTX) ).
On August 13, 2025, Heron Therapeutics‘ Board of Directors adopted a Tax Benefit Preservation Plan to protect the company’s net operating loss carryforwards (NOLs), valued at approximately $1.37 billion as of December 31, 2024. The plan, effective August 14, 2025, aims to deter any single investor or group from acquiring 4.99% or more of Heron’s outstanding common stock, which could trigger an ‘ownership change’ under Section 382 of the Internal Revenue Code and limit the company’s ability to use its NOLs to offset future taxable income. This strategic move is intended to enhance Heron’s financial position and support its growth strategy.
The most recent analyst rating on (HRTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics faces significant financial challenges with high leverage and ongoing losses, impacting its overall score. While technical indicators show bearish momentum, recent corporate events and strategic initiatives provide some positive outlook. The valuation remains unattractive due to negative earnings.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving patient care through the development and commercialization of therapeutic innovations. The company aims to advance the standard-of-care for acute care and oncology patients using advanced science, patented technologies, and innovative drug discovery approaches.
Average Trading Volume: 1,535,057
Technical Sentiment Signal: Strong Sell
Current Market Cap: $206.9M
Learn more about HRTX stock on TipRanks’ Stock Analysis page.